» Articles » PMID: 30287142

CCL20, a Direct-acting Pro-angiogenic Chemokine Induced by Hepatitis C Virus (HCV): Potential Role in HCV-related Liver Cancer

Overview
Journal Exp Cell Res
Specialty Cell Biology
Date 2018 Oct 6
PMID 30287142
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The CCL20/CCR6 chemokine/receptor axis has previously been shown to contribute to the initiation and progression of hepatocellular carcinoma (HCC) through the recruitment of CCR6-positive leukocytes to the tumor microenvironment. In particular, high serum levels of CCL20 are reported in patients with HCC induced by the hepatitis C virus (HCV). A potential non-immune role for the CCL20/CCR6 axis in HCC development has not yet been investigated. Microarray analysis (Benkheil et al., paper submitted for publication), revealed that CCL20 is highly upregulated in hepatoma cells infected with HCV compared with non-infected hepatoma cells. To determine the role of the CCL20/CCR6 axis in HCV-related HCC, we first explored which cell populations express CCR6 in human liver tissue with chronic disease or HCC. Immunohistochemical (IHC) analysis revealed that CCR6 is present on endothelial cells (ECs) of portal blood vessels in livers with chronic HCV infection and in HCV- and alcoholic-HCC tissue. In addition, we found CCR6 to be expressed on primary macrovascular (HUVECs) and microvascular ECs (HMVEC-ds) where it co-expressed with the endothelial marker CD31. In vitro angiogenesis experiments revealed that CCL20 is a direct pro-angiogenic molecule that induces EC invasion, sprouting and migration through CCR6. Moreover, using the angiogenesis matrigel plug assay in immunodeficient NMRI-nu mice, we clearly showed that CCL20 induces blood vessel formation, by attracting CCR6-positive ECs. Finally, we demonstrated that HCV-induced CCL20 protein expression and secretion in hepatoma cells could be abolished by antiviral treatment, indicating that CCL20 expression is dependent on HCV replication. In contrast to HCV, HBV-infection resulted in a decreased expression of CCL20, implying a virus-specific effect. Taken together, we identified HCV-induced CCL20 as a direct pro-angiogenic factor that acts on endothelial CCR6. These results suggest that the CCL20/CCR6 axis contributes to hepatic angiogenesis, promoting the hypervascular state of HCV-HCC.

Citing Articles

CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.

Kwantwi L, Boafo J, Egleh B, Li M Clin Transl Oncol. 2025; .

PMID: 39985603 DOI: 10.1007/s12094-025-03874-5.


Targeting PADI2 as a potential therapeutic strategy against metastasis in oral cancer via suppressing EMT-mediated migration and invasion and CCL3/5-induced angiogenesis.

Hung S, Yu C, Lin H, Chiou W, Lee M, Lin R Clin Exp Metastasis. 2024; 41(6):925-935.

PMID: 39215870 DOI: 10.1007/s10585-024-10310-5.


The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma.

Wu Z, Sun L, Xu Y, Huang H, Wu Z, Qiu B Cancer Manag Res. 2024; 16:403-420.

PMID: 38736589 PMC: 11086648. DOI: 10.2147/CMAR.S450959.


HOXD3 promotes the migration and angiogenesis of hepatocellular carcinoma via modifying hepatocellular carcinoma cells exosome-delivered CCR6 and regulating chromatin conformation of CCL20.

Wang L, Qiao C, Han L, Wang X, Miao J, Cao L Cell Death Dis. 2024; 15(3):221.

PMID: 38493218 PMC: 10944507. DOI: 10.1038/s41419-024-06593-x.


The chemokine CCL20 can assist AFP in serological diagnosis of hepatocellular carcinoma.

Deng Q, Zhang X, Wan X, Zheng X, Wang H, Zhao J Heliyon. 2024; 10(5):e26774.

PMID: 38439882 PMC: 10909724. DOI: 10.1016/j.heliyon.2024.e26774.